硼替佐米联合自体造血干细胞移植治疗多发性骨髓瘤的临床分析

Clinical Analyses of Bortezomib Combined with Autologous Hematopoietic Stem Cell Transplantation in the Treatment of Multiple Myeloma

目的探讨硼替佐米联合自体造血干细胞移植治疗多发性骨髓瘤的疗效和安全性。方法对1例轻链型多发性骨髓瘤患者,采用VTD方案(硼替佐米1.3 mg/m2,d 1、4、8、11;沙利度胺200 mg,d 1～14;地塞米松10 mg,d 1～4、d 9～12)化疗3个周期获得完全缓解后再行自体造血干细胞移植,监测M蛋白、肝肾功能、骨髓像、血象等指标,移植后再行白介素-2的免疫治疗。结果自体造血干细胞移植后患者造血重建顺利,相关并发症控制较好,随访至今一直无病生存。结论硼替佐米联合自体造血干细胞移植治疗多发性骨髓瘤是安全有效的。

Objective To evaluate the efficacy and safety of bortezomib combined with autologous hematopoietic stem cell transplantation in a case of multiple myeloma.Methods 1 patient with light chain multiple myeloma was treated with 3 courses of VTD（bortezomib 1.3 mg/m2,d1,4,8,11;thalidomide 200 mg,d1～14;dexamethasone 10 mg,d1～4,9～12） and autologous stem cell transplantation after complete remission followed by interleukin-2 immunotherapy after transplantation.The M protein,liver and kidney function,bone marrow,and routine blood count were monitored.Results Patients engrafted successfully after autologous hematopoietic stem cell transplantation.The patient was alive without severe complication.Conclusion Bortezomib combined with autologous hematopoietic stem cell transplantation is safe and effective in the treatment of multiple myeloma.